The ASCO Post

Founded in 2010, The ASCO Post collaborates with the American Society of Clinical Oncology (ASCO) to share vital information about evidence-based cancer care with a wide range of oncology experts and ASCO members. The ASCO Post is available both in print and online. Each edition highlights reliable reports on clinical cancer research, updates on policies, patient care topics, issues in clinical practice, and insightful opinions from prominent figures in the field of clinical oncology.

National, Trade/B2B

English

Newspaper

Outlet metrics

Domain Authority

Ranking

Global

#428873

United States

#237540

Health/Health Conditions and Concerns

#625

Traffic sources

Monthly visitors

Articles

CRISPR-Cas9-Edited TILs: Targeting Intracellular Immune Checkpoint CISH in Metastatic Colorectal Cancer

3 days ago | ascopost.com | Matthew Stenger

In a first-in-human, single-institution phase I trial reported in The Lancet Oncology, Lou et al found that autologous tumor infiltrating lymphocytes (TILs) genetically edited with CRISPR-Cas9 to target the intracellular immune checkpoint CISH were tolerable and showed evidence of activity in patients with metastatic colorectal cancer. The TILs are edited to enable knockout of CISH, which encodes cytokine-inducible SH2-containing protein, a novel intracellular immune checkpoint target.
In Case You Missed It: Additional Abstracts of Interest From AACR

3 days ago | ascopost.com | Caroline Helwick |Chase Doyle

Thousands of forward-looking research studies defined the 2025 American Association for Cancer Research (AACR) Annual Meeting. Here, aside from our fuller coverage of key presentations in The ASCO Post, we offer a snapshot of a few additional abstracts that may be of interest to cancer researchers and clinicians.
Effects of Tumor-Infiltrating Clonal Hematopoiesis

3 days ago | ascopost.com | Matthew Stenger

In a study reported in The New England Journal of Medicine, Pich et al found that tumor-infiltrating clonal hematopoiesis (TI-CH) was associated with an increased risk of death or recurrence among patients with early-stage non–small cell lung cancer (NSCLC) and poorer overall survival among patients with a range of solid tumors.
ASH Studies Bolster Support for Menin Inhibitor in Acute Leukemia

1 week ago | ascopost.com | Caroline Helwick

The recent approval of the oral menin inhibitor revumenib brought much-needed treatment to patients with a challenging subset of disease: adults and children with relapsed or refractory acute leukemia harboring a lysine methyltransferase 2A gene (KMT2A) translocation or rearrangement.
Quick Takes on Research Findings on Novel Therapies for Gynecologic Cancers

1 week ago | ascopost.com | Caroline Helwick

The 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer advanced the field with updates of practice-changing trials and other research that challenges the conventional approaches to treating gynecologic cancers. We have briefly captured some of that research here for readers of The ASCO Post.
Everolimus Plus Lanreotide vs Everolimus Alone in Aggressive Gastroenteropancreatic Neuroendocrine Tumors

1 week ago | ascopost.com | Caroline Helwick

In patients with aggressive gastroenteropancreatic neuroendocrine tumors, first-line treatment with the mTOR inhibitor everolimus and the somatostatin analog lanreotide more than doubled the median progression-free survival for patients vs everolimus alone, in the phase III JCOG1901 (STARTER-NET) trial conducted in Japan.1 “Everolimus plus lanreotide has the potential to become a new standard first-line treatment of patients with unresectable or recurrent gastroenteropancreatic neuroendocrine...
Survival Trends in Melanoma Brain Metastases: Update of Melanoma Graded Prognostic Assessment

1 week ago | ascopost.com | Matthew Stenger

In a study reported in Journal of Clinical Oncology, Sperduto and colleagues analyzed trends in survival associated with newly diagnosed melanoma brain metastases and updated the Melanoma Graded Prognostic Assessment (GPA).
Outcomes With HSCT in Pediatric High-Risk AML

1 week ago | ascopost.com | Matthew Stenger

In a Children’s Oncology Group (COG) study (AAML1831) reported in Journal of Clinical Oncology, Huang et al found that hematopoietic stem cell transplantation (HSCT) was associated with improved outcomes in pediatric patients with high-risk acute myeloid leukemia (AML).
Symptoms Preceding Unplanned Acute Care in Patients With Cancer

1 week ago | ascopost.com | Matthew Stenger

In a single-institution cohort study reported in JAMA Network Open, Chang et al identified patterns of symptoms preceding unplanned acute care encounters for patients with cancer. Study DetailsThe study involved data from all unplanned acute care encounters (emergency department visits and hospitalizations) among patients with a primary cancer diagnosis at University of California, San Francisco between January 2013 and December 2023.
Addition of Perioperative Pembrolizumab to Standard of Care in Newly Diagnosed Locally Advanced Head and Neck Cancer

1 week ago | ascopost.com | Caroline Helwick

In the phase III KEYNOTE-689 trial, perioperative use of the PD-1 inhibitor pembrolizumab given with standard therapy significantly improved event-free survival in newly diagnosed, previously untreated patients with locally advanced head and neck squamous cell carcinoma, researchers reported at the 2025 American Association for Cancer Research (AACR) Annual Meeting.1 These patients were also significantly more likely to achieve a major pathologic response.